NewsGlobeNewswire
BioAge Labs Reports Third Quarter 2026 Financial Results and Provides Business Updates
· Published
Article summary
First participant dosed in QUELL-DME, a Phase 2 trial of BGE-102, a potential best-in-class oral NLRP3 inhibitor, in diabetic macular edema; topline results anticipated in the second half of 2027
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…